Oruka Therapeutics, Inc. (ORKA)
95.78
-0.03
(-0.03%)
USD |
NASDAQ |
Oct 28, 12:05
Oruka Therapeutics EPS Diluted (Quarterly) : -0.6554 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.6554 |
| March 31, 2026 | -0.5767 |
| December 31, 2025 | -0.5436 |
| September 30, 2025 | -0.6871 |
| June 30, 2025 | -0.5838 |
| March 31, 2025 | -0.5038 |
| December 31, 2024 | -0.6424 |
| September 30, 2024 | -1.906 |
| June 30, 2024 | -6.955 |
| March 31, 2024 | -318.67 |
| December 31, 2023 | -0.9012 |
| September 30, 2023 | -1.186 |
| June 30, 2023 | -1.232 |
| March 31, 2023 | -1.121 |
| December 31, 2022 | -0.9776 |
| September 30, 2022 | -1.943 |
| June 30, 2022 | -2.621 |
| March 31, 2022 | -2.725 |
| December 31, 2021 | -4.727 |
| September 30, 2021 | -3.924 |
| June 30, 2021 | -4.026 |
| March 31, 2021 | -3.982 |
| December 31, 2020 | -6.441 |
| September 30, 2020 | -3.953 |
| June 30, 2020 | -8.710 |
| Date | Value |
|---|---|
| March 31, 2020 | -9.937 |
| December 31, 2019 | -9.229 |
| September 30, 2019 | -9.119 |
| June 30, 2019 | -13.64 |
| March 31, 2019 | -22.29 |
| December 31, 2018 | -23.10 |
| September 30, 2018 | -24.71 |
| June 30, 2018 | -32.83 |
| March 31, 2018 | -43.37 |
| December 31, 2017 | -76.99 |
| September 30, 2017 | -83.24 |
| June 30, 2017 | -127.91 |
| March 31, 2017 | -103.03 |
| December 31, 2016 | -100.93 |
| September 30, 2016 | -110.16 |
| June 30, 2016 | -92.88 |
| March 31, 2016 | -86.40 |
| December 31, 2015 | -75.60 |
| September 30, 2015 | -66.96 |
| June 30, 2015 | -151.20 |
| March 31, 2015 | -196.56 |
| December 31, 2014 | -186.66 |
| September 30, 2014 | -166.32 |
| June 30, 2014 | -166.32 |
| March 31, 2014 | -196.56 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Tenax Therapeutics, Inc. | -0.35 |
| Exicure, Inc. | -0.1759 |
| Century Therapeutics, Inc. | -0.1679 |
| Absci Corp. | -0.2109 |
| Celularity, Inc. | 0.0186 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -41.21M |
| Total Expenses (Quarterly) | 41.21M |
| Enterprise Value | 4.983B |
| Earnings Yield | -2.57% |
| Normalized Earnings Yield | -2.571 |